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Abstract 
Background: Due to their self‑renewal capacity, multi‑lineage potential, and immunomodulatory properties, mes‑
enchymal stromal cells (MSCs) are an attractive tool for different therapeutic strategies. Foreskin (FSK), considered as a 
biological waste material, has already been shown to be a valuable source of MSCs. Besides their typical fibroblast like 
morphology and International Society for cellular Therapy compliant phenotype, foreskin‑MSCs (FSK–MSCs) are clo‑
nogenic, and highly proliferative cells with multi‑lineage and strong immunomodulatory capacities. Of importance, 
FSK–MSCs properly adjust their fate following exposure to inflammatory signals. Being potent regulators of gene 
expression, miRNAs are involved in modulating nearly all cellular processes and in orchestrating the roles of different 
immune cells. In this study, we characterized the miRNome of FSK–MSCs by determining the expression profile of 380 
different miRNAs in inflammation primed vs. control non‑primed cells.
Methods: TaqMan low density array (TLDA) was performed to identify dysregulated miRNAs after exposing FSK–
MSCs to inflammatory signals. Quantitative real‑time RT‑PCR was carried out to validate the observations. DIANA‑miR‑
Path analysis web server was used to identify potential pathways that could be targeted by the dysregulated miRNAs.
Results: Sixteen miRNAs were differentially expressed in inflammation‑primed vs. non‑primed FSK–MSCs. The expres‑
sion level of miR‑27a, ‑145, ‑149, ‑194, ‑199a, ‑221, ‑328, ‑345, ‑423‑5p, ‑485‑3p, ‑485‑5p, ‑615‑5p and ‑758 was down‑
regulated whilst that of miR‑155, ‑363 and ‑886‑3p was upregulated. Target pathway prediction of those differentially 
expressed miRNAs identified different inflammation linked pathways.
Conclusions: After determining their miRNome, we identified a striking effect of inflammatory signals on the miR‑
NAs’ expression levels in FSK–MSCs. Our results highlight a potential role of miRNAs in modulating the transcription 
programs of FSK–MSCs in response to inflammatory signals. Further, we propose that specific miRNAs could serve as 
interesting targets to manipulate some functions of FSK–MSCs, thus ameliorating their therapeutic potential.
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Background
Mesenchymal stromal cells (MSCs) are multipotent fibro-
blast-like cells found in almost all tissues [1]. This multi-
lineage potential, along with their capacity of supporting 
hematopoiesis and modulating immune responses are 
the main properties of MSCs. The simple and easy iso-
lation procedures together with the great expansion 
potential, render MSCs as ideal candidates for different 
cellular therapies [2]. Despite some common character-
istics and properties shared by MSCs of different origin 
[3], significant differences in their immunobiological fea-
tures exist [4, 5]. Although it has long been considered as 
a biological waste material, foreskin (FSK) is, nowadays, 
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having potential value for several clinical applications 
[6, 7]. Recently, we have demonstrated that the foreskin 
is a new source of MSCs, designated as FSK–MSCs [8]. 
Being compliant with ISCT criteria, non-immunogenic 
and showing powerful immunomodulatory capacities 
[8], FSK–MSCs are highlighted as a valuable tolerogenic 
tool for cell-based immunotherapy. As known, MSCs are 
particularly sensitive to the local inflammatory microen-
vironment that modulate their functions and responses. 
Indeed, inflammation-priming leads to significant 
changes in the immunobiology of FSK–MSCs [8].
MicroRNAs (miRNAs) are small (19-22-nt) single-
stranded noncoding RNA molecules that regulate the 
transcription or translation of the target gene mRNAs. 
Thus, they play crucial roles in many different cellular 
processes including cell differentiation, proliferation and 
immune homeostasis [9–12]. Accumulating data show 
that abnormal miRNA expression is a common feature of 
various diseases [9–12]. Nowadays, many evidences dem-
onstrate a role for miRNAs in regulating distinct aspects 
of the immune system including cell proliferation, dif-
ferentiation, fate determination and function mediated 
by different cell types [13–15]. The understanding of the 
miRNome of FSK–MSCs under inflammatory settings 
will help to identify the pattern of miRs that are modu-
lated and that could serve as targets to enhance MSCs 
therapeutic functions. In this study, comparative analysis 
showed that the miRNA expression profile of FSK–MSCs 
is critically different in inflammation primed vs. control 
non-primed cells. Our results reveal specific miRNA 
expression differences following inflammation priming 
and identified 16 differentially expressed miRNAs. Those 
altered miRNAs might be involved in the molecular 
mechanisms regulating FSK–MSCs immunobiology dur-
ing inflammatory conditions and could be further used as 
targets to manipulate FSK–MSCs functions.
Methods
Ethical guidelines
This study was conducted in accordance with the Decla-
ration of Helsinki (1964) and approved by the local eth-
ics committee of the “Institut Jules Bordet” (Belgium). All 
donors and/or their parents or legal guardian were volun-
tary for giving the foreskin (FSK) samples as obtained fol-
lowing a circumcision procedure from healthy subjects. 
They gave written informed consent before specimen col-
lection for using the samples and for publishing any asso-
ciated scientific data. However, all personal information 
are kept confidential.
Isolation, culture and characterization of FSK–MSCs
Briefly, after circumcision, foreskin was aseptically col-
lected into a sterile specimen container containing sterile 
phosphate-buffered saline (PBS) buffer supplemented with 
penicillin/streptomycin. The samples were processed as 
previously published [8]. After a sterile wash with PBS, the 
sample was transferred into a petri dish where epidermis 
was manually removed from the skin and the dermis was 
cut into small pieces. By using Liberase Research Grade 
solution (Roche Diagnostics, Belgium), the tissue was 
digested and the resulting cell suspension was washed by 
centrifugation (800g, 5 min) in Dulbecco’s modified Eagle’s 
medium with low glucose (DMEM-LG; Lonza, Belguim) 
and containing 10% fetal bovine serum (FBS; Sigma-
Aldrich, Belgium). The subsequent cell pellet was seeded in 
culture flasks with DMEM-LG (Lonza) supplemented with 
10% FBS (Sigma-Aldrich), 2  mM l-glutamine and 50  U/
ml penicillin (both from Lonza) and the cultures were 
incubated at 37  °C in a 5% CO2 humidified atmosphere. 
Non-adherent cells were removed when the medium was 
changed (once a week). When sub-confluence (80–90%) 
was achieved, adherent cells were harvested by TrypLE 
Select (Lonza) and expanded until the desired passage.
The cells were characterized according to the ISCT 
criteria. Thus, the immunophenotype was analysed by 
flow cytometry (MacsQuant analyzer (Miltenyi Biotec, 
Netherlands)) using fluorochrome labelled monoclo-
nal antibodies: anti-CD45-FITC and anti-HLA-Dr-PE 
(Exalpha Biologicals, Maynard, MA), anti-CD34-PE and 
anti-CD73-PE (BD Biosciences, San Diego, CA, USA), 
anti-CD14-PE, anti-CD19-PE, anti-CD105-FITC and 
anti-CD90-PE (R&D systems, Minneapolis, MN, USA). 
Their multilineage potential was confirmed by induc-
ing specific lineage commitment (adipogenic, osteogenic 
and chondrogenic differentiation) using appropriate 
induction culture medium (NH media, Miltenyi Biotec). 
Specific lineage commitment was highlighted by using 
lineage-specific cell staining techniques and microscopic 
examination.
Inflammation priming of FSK–MSCs
Foreskin–mesenchymal stromal cells were analyzed 
under both constitutive and inflammatory conditions. 
Inflammation priming of FSK–MSCs was performed 
as previously described [16]. Briefly, cells were treated 
(overnight) with a pro-inflammatory cytokine cock-
tail containing IL-1β (Peprotech, Rocky Hill, NJ, USA) 
(25  ng/ml), TNF-α (50  ng/ml), IFN-α (3000  U/ml or 
10 ng/ml) and IFN-γ (1000 U/ml or 50 ng/ml) (all from 
Prospec Inc., Rehovot, Israel). After priming, the medium 
was removed, and the cells were washed and became 
available for analysis.
MiRNA expression profile
Total RNA was extracted from cells using TRIzol total 
RNA isolation reagent (Roche Applied Science). The 
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concentration was quantified using a NanoDrop spec-
trophotometer. A three-step procedure was performed 
to profile the miRNAs. First, for cDNA synthesis from 
the miRNAs, 30  ng of total RNA was subjected to RT 
(reverse transcription) using a TaqMan® microRNA 
Reverse Transcription Kit (#4366596; Applied Bio-
systems) and Megaplex RT primers (Human Pool A, 
#4399966; Applied Biosystems) following the manufac-
turer’s protocol, allowing simultaneous reverse transcrip-
tion of 380 mature human miRNAs to generate a miRNA 
cDNA library corresponding to each plasma sample. RT 
was performed on a Mastercycler Epgradient thermocy-
cler (Eppendorf ) with the following cycling conditions: 
40 cycles at 16 °C for 2 min, 42 °C for 1 min and 50 °C for 
1 s followed by a final step of 80  °C for 5 min to inacti-
vate reverse transcriptase. Thereafter, to generate enough 
miRNA cDNA template for the following real-time PCR, 
the cDNA libraries were pre-amplified using Megaplex 
PreAmp primer (Humam Pool A, #4399233; Applied Bio-
systems) and PreAmp Master Mix (#4384266; Applied-
Biosystems) following the manufacturer’s instructions. 
The PreAmp primer pool used here consisted of forward 
primers specific for each of the 380 human miRNAs and 
a universal reverse primer. The pre-amplification cycling 
conditions were as follows: 95  °C for 10  min, 55  °C for 
2 min, 72 °C for 2 min followed by 12 cycles at 95 °C for 
30 s and 60 °C for 4 min; the samples were then held at 
99.9  °C for 10 min. After the pre-amplification step, the 
products were diluted with RNase-free water, com-
bined with TaqMan gene expression Master Mix and 
then loaded into TaqMan Human MicroRNA Array A 
(#4398965; Applied Biosystems), which is a 384-well for-
matted plate and real-time PCR-based microfluidic card 
with embedded TaqMan primers and probes in each well 
for the 380 different mature human miRNAs. Real-time 
PCR was performed on an ABI PRISM 7900HT sequence 
detection system (Applied Biosystems) with the following 
cycling conditions: 50 °C for 2 min, 94.5 °C for 10 min fol-
lowed by 40 cycles at 95 °C for 30 s and 59.7 °C for 1 min. 
The Ct (cycle threshold) was automatically given by SDS 
2.4 software (Applied Biosystems) and is defined as the 
fractional cycle number at which the fluorescence passes 
the fixed threshold of 0.2. RNU48 embedded in the 
TaqMan human microRNA arrays was used as an endog-
enous control. The relative expression levels of miRNAs 
were calculated using the comparative ΔΔCt method as 
described previously [17, 18]. The fold changes in miR-
NAs were calculated by the equation 2−ΔΔCt.
Taqman miRNA assay for individual miRNAs
Gene-specific reverse transcription was performed for 
each miR using 10  ng of purified total RNA, 100  mM 
dNTPs, 50 U MultiScribe reverse transcriptase, 20  U 
RNase inhibitor, and 50  nM of gene-specific RT primer 
samples using the TaqMan MicroRNA Reverse Transcrip-
tion kit (Applied Biosystems, Gent, Belgium). 15 μl reac-
tions were incubated for 30 min at 16 °C, 30 min at 42 °C, 
and 5 min at 85 °C to inactivate the reverse transcriptase. 
Real time RT-PCR reactions (5  μl of RT product, 10  μl 
TaqMan 2 × Universal PCR master Mix, (Applied Biosys-
tems, Gent, Belgium), and 1 μl TaqMan MicroRNA Assay 
Mix containing PCR primers and TaqMan probes) were 
carried out on ABI Prism 7900HT Sequence Detection 
System (Applied Biosystems, Gent, Belgium) at 95 °C for 
10 min followed by 40 cycles at 95 °C for 15 s and 60 °C for 
1 min. The qRT-PCR reactions were performed in tripli-
cate, and the signal was collected at the end of every cycle. 
The Ct (cycle threshold) was automatically given by SDS 
2.4 software (Applied Biosystems) and is defined as the 
fractional cycle number at which the fluorescence passes 
the fixed threshold of 0.2.
RNU48 was used as an endogenous control. The rela-
tive expression levels of miRNAs were calculated using 
the comparative ΔΔCt method as described previously 
[31, 32]. The fold changes in miRNAs were calculated by 
the equation 2−ΔΔCt.
Pathway enrichment analysis
Pathway enrichment analysis was employed to investigate 
the regulatory mechanisms of significantly differentially 
expressed miRNAs. DIANA-miRPath v.3.0 analysis web 
server was used for pathway enrichment analyses. The 
enriched pathways were defined by their enrichment of 
significantly differentially expressed miRNA target genes.
Statistical analysis
Data analyses were performed using the SDS RQ Man-
ager 1.2 software and DataAssist v2.0 software (Applied 
Biosystems). Statistical significance of miRNA expres-
sion between control and treated cells was determined 
according to unpaired Mann–Whitney U test. p Values 
<0.05 (*), <0.01 (**) were considered significant.
Results
Obtaining and characterizing FSK–MSCs
In order to obtain FSK–MSCs, the foreskin sample was 
first processed to separate the epidermis from the dermis 
(see "Methods" section) and then scraping was applied 
to obtain small tissue pieces from the dermis. Following 
enzymatic digestion, the tissue mixture was centrifuged 
and the resulting cell pellet was incubated for culture. 
After removing non adherent cells, colonies of cells with 
fibroblastic morphology started to appear. When sub-
confluency (80–90%) was reached, adherent cells were 
harvested using TrypLE Select solution and expanded by 
successive passages.
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These adherent cells were then characterized accord-
ing to the ISCT criteria. Flow cytometry analysis demon-
strated that those cells are positive (>95%) for the MSC 
markers CD73, CD90 and CD105 whilst negative (<5%) 
for CD45, CD34, CD14, CD19 and HLA-DR markers. 
It is noteworthy that inflammation priming had no sig-
nificant impact on the expression level of those markers 
(data not shown).
To comply with the ISCT criteria, we further con-
firmed that the obtained cells exhibited a multi-lineage 
potential since they were able to differentiate into cells 
of adipogenic, osteogenic or chondrogenic lineage after 
being cultured with appropriate induction media (data 
not shown). After 21  days of osteogenic differentiation, 
a mineralization matrix following calcium deposits was 
observed by Alizarin red staining demonstrating the gen-
eration of osteoblasts. After 10 days of adipogenic differ-
entiation, cells with cytoplasm containing several lipid 
vacuoles were revealed by Oil Red O staining indicating 
the formation of adipocytes. After 21  days of chondro-
genic differentiation, the production of proteoglycans-
based extracellular matrix was shown by Alcian blue 
staining illustrating the generation of chondrocytes.
Impact of inflammation priming on miRNA‑expression 
profile in FSK–MSCs cells
Aware that MSCs can serve as sensors and switchers of 
inflammation, and given the importance of miRNAs in 
regulating inflammatory responses, we aimed at char-
acterizing the expression level of different miRNAs in 
FSK–MSCs and investigating the impact of inflammation 
on this expression. FSK–MSCs were derived from 5 inde-
pendent donors and total RNA was prepared from those 
cells being either untreated (control cells) or treated with 
a pro-inflammatory cytokine cocktail (treated cells). 
TaqMan low density array (TLDA) was then carried out 
to assess miRNA expression level in those cells. Before 
measuring miRNAs’ levels and in order to identify suit-
able endogenous controls, three different candidate 
miRNAs (RNU44, RN48, and U6 snRNA) were analyzed 
for variance in gene expression using Data Assist soft-
ware v2.0. The statistical method ranked the candidate 
endogenous control genes with an excellent correlation 
of raw stability values (data not shown). The most stably 
expressed RNU48 was chosen as the endogenous control, 
and relative miRNA expression was normalized against 
RNU48. Our TLDA analysis revealed that the miRNA 
expression profile in treated cells is not totally similar 
to that of untreated cells. In fact, we show the expres-
sion level of 25 miRNAs that were modulated in treated 
vs. control cells (Fig. 1). Among these, 20 miRNAs (miR-
145, -149, -182, -194, -199a, -221, -27a/b, -328, -330-5p, 
345, -34c, -361, -369-5p, -423-5p, 485-3p, 485-5p, -494, 
-615-5p and-758) were downregulated whilst 5 miRNAs 
(miR-107, -155, -183, -363 and -886-3p) were upregu-
lated. Details of the results are shown in Table  1. A 
clustergram of the samples as well as the significantly dif-
ferentially expressed miRNAs in control and treated cells 
are illustrated in Fig. 1 in the form of a heat map gener-
ated using ΔCt values. Heat map is a typical method used 
in gene-expression analysis where the expression level 
of many genes across a number of tested samples can be 
displayed in a two dimensional image with a color code 
representing the expression intensity of each gene.
The numbers corresponding to these colors are the ΔCt 
values. The dendrogram on the left side of the heat map 
classifies miRNAs into groups based on the divergence of 
miRNA expression values among the different samples. 
The dendrogram presented at the top indicates the relat-
edness of the samples based on overall miRNA expres-
sion values and separates the control from the treated 
group of samples.
In a second step, and in order to validate their differ-
ential expression, miRNAs that appeared to be upregu-
lated or downregulated in treated vs. control cells were 
further examined using individual quantitative Real Time 
PCR (qRT-PCR). Interestingly, out of the 25 miRNAs 
that showed altered expression (Table  1), 16 miRNAs 
were confirmed to exhibit such differential expression in 
treated vs. control cells (Fig. 2). Those 16 miRNAs fall in 
two groups. Group 1 contains 13 miRs that were down-
regulated (ratio between 0.1and 0.005) in treated cells in 
comparison to control cells and includes miR-27a, -145, 
-149, -194, -199a, -221, -328, -345, -423-5p, -485-3p, 
-485-5p, -615-5p and -758 (Fig. 2). Observing that those 
16 miRs are not equal in terms of their downregulation 
rate led us to further classify them into subgroups. Group 
1A corresponds to miRNAs that were most strikingly 
downregulated and consists of miR-27a, -145 and -221 
that decreased 10, 13.7 and 15 folds, respectively. Group 
1B consists of miRNAs that were less strikingly down-
regulated and includes miR-149, -194, -615-5p and -758 
that exhibited decreased rates of 7, 8.4, 5 and 5.3 folds, 
respectively. Group 1C contains the least strongly down-
regulated miRNAs and includes miR-199a, -328, -345, 
-423-5p, 485-3p and -485-5p that showed downregula-
tion rates of 3.8, 2, 4.8, 2.5, 3.4 and 3.7 folds, respectively.
On the other hand, group 2 contains 3 miRNAs 
(miR-155, -363 and -886-3p) that were upregulated 
(ratio greater than 3) in treated vs. control cells (Fig. 2). 
Among these, miR-155 was the most strikingly upregu-
lated miR exhibiting a 9.4 fold increase whilst miR-363 
and -886-3p showed increased rates of 4.7 and 4.5 folds, 
respectively. Altogether, these observations demonstrate 
a clear difference in the miRNA expression profile in 
FSK–MSCs exposed to inflammatory signals vs. control 
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cells suggesting a potential role for miRNAs in modulat-
ing FSK–MSCs’ transcriptional programs in response to 
inflammatory conditions.
Analysis of inflammation primed MSCs–associated miRNA 
pathways
Since each miRNA can regulate the expression of many 
target genes but multiple miRNAs can modulate specific 
pathways, we explored the pathways that were poten-
tially regulated by the miRNAs observed to be altered 
in inflammation primed FSK–MSCs in comparison to 
untreated control MSCs.
For the identification of these pathways, DIANA-
miRPath v.3.0 analysis web server was used and each of 
the statistically differentially expressed miRNAs was 
used as a query. The output Kyoto encyclopedia of genes 
C4C2 C3C1 C5 T1 T2 T3 T4 T5
Fig. 1 Differentially expressed miRNAs in inflammation‑primed FSK–MSCs. Heat map presenting the differentially expressed miRNAs in inflamma‑
tion‑primed FSK–MSCs compared to their respective untreated partners (n = 5 in each group). MiRNA expression data was generated by perform‑
ing TaqMan low‑density arrays (TLDA). Columns correspond to inflammation‑cocktail treated samples (T) or untreated control samples (C). Each row 
corresponds to an individual miRNA sequence. Only miRNAs significantly modulated (p < 0.05) are included in the map. The colors display miRNA 
expression variance where red indicates an increased abundance of miRNA in the indicated samples whereas green indicates a reduced miRNA level
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and genomes (KEGG) pathways obtained for each miR 
included many results and for reasons of simplicity and 
specificity we focused only on pathways linked to inflam-
mation. These pathways were previously summarized in 
[19] and included Adhesion-Extravasation-Migration, 
apoptosis signaling, calcium signaling, cytokine signaling, 
leukocyte signaling, innate pathogen detection, MAPK 
signaling, NF-κB signaling, PI3  K-AKT signaling, TNF 
superfamily signaling, NK cell signaling, GPCR signal-
ing, ROS/Glutathione/cytotoxic granules, phagocytosis-
antigen presentation, complement cascade, Eicosanoid 
signaling and Glucocorticoid signaling/PPAR signaling. 
The pathways targeted by upregulated and downregu-
lated miRs are shown in Table 2. It is noteworthy that no 
KEGG pathways linked to inflammation were identified 
for miR-149, -328, -345, -363, -423-5p, -615-5p, -758 and 
-886-3p.
Discussion
In addition to their self-renewing and multi-lineage dif-
ferentiation properties, MSCs exhibit immunoregulatory 
abilities through influencing both immune and inflamma-
tory responses [20]. In fact, MSCs, can actively sense the 
surrounding microenvironment or inflammatory milieu 
and adopt their phenotype and responses, accordingly 
[20]. For instance, and depending on the environmental 
signals, MSCs can play both pro- and anti-inflammatory 
roles [20]. This marked functional plasticity of MSCs ren-
ders them as clinically relevant cell types with important 
therapeutic potential for tissue repair and regeneration as 
well as for the treatment of different inflammatory diseases 
and malignancies [20, 21]. Nowadays, different popula-
tions of MSCs, derived from distinct human tissues, are 
available and exhibit dissimilar immunological profiles and 
functional capacities [5, 22, 23]. FSK–MSCs are emerg-
ing as a highly interesting MSC-type due to their recently 
characterized properties [8]. Besides, FSK–MSCs, when 
exposed to inflammatory conditions, have been shown to 
exhibit induced expression of different immunoregulatory 
genes and factors [8]. Their high sensitivity to inflamma-
tion increased the interest in understanding the molecular 
mechanisms involved in coupling FSK–MSCs’ responses 
to the surrounding inflammatory microenvironment.
Among the different regulatory elements that controls 
gene expression and modulates cellular fate and behav-
ior are miRNAs. For instance, they can significantly alter 
the responses of different innate and adaptive immune 
cells where any disturbance of their expression profiles 
can lead to several diseases [24–27]. Therefore, miRNAs 
are, nowadays, considered as attractive therapeutic tar-
gets [24–27]. Besides their ability to modulate immune 
responses, miRNAs play a key role in MSCs’ biology. For 
example, miRNAs can strikingly affect MSCs’ decision to 
either proliferate or differentiate into either cell lineage 
including adipogenic, chondrogenic, myogenic, neuro-
genic or other lineages [28]. The aim of this work was to 
determine the miRNome of FSK–MSCs by investigating 
the expression profile of 380 different miRNAs in inflam-
mation primed vs. control non-primed cells. The major 
outcome of this study is our demonstration of a signifi-
cantly altered miRNA expression profile in inflamma-
tion-primed FSK–MSCs where 16 miRNAs were found 
Table 1 MiRNA signature identified by TLDA Technique
Our TLDA analysis identified 25 miRNAs to be differentially expressed in treated 
vs. untreated control cells with a p value <0.05


























(See figure on next page.) 
Fig. 2 Sixteen miRNAs are differentially expressed after inflammation priming of FSK–MSCs. FSK–MSCs, derived from 5 independent donors, were 
cultivated in the absence or presence of inflammatory cocktail. RNU48‑normalized miRNA levels were quantified by qRT‑PCR and plotted as Box 
plots. The statistical significance was determined using Mann–Whitney U‑ test (*p <  0.05, **p < 0.01 vs. untreated control cells)
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to be differentially expressed. This observed inflamma-
tion-triggered alteration of miRNA expression pattern 
is not surprising especially that different miRNAs have 
been reported to show altered expression in response to 
inflammatory signals. For example, miR-146 expression 
level is described to be upregulated in response to inflam-
matory stimuli [29], whilst other miRNAs including miR-
9, -101, -125b, -155, -146, -192 and -203 are described to 
exhibit altered expression profiles in some inflammatory 
diseases [30].
We classified our differentially expressed miRNAs in 
two major groups: (1) a first one containing the miRNAs 
being downregulated in inflammation-primed FSK–
MSCs and includes miR-27a, -145, -149, -194, -199a, 
-221, -328, -345, -423-5p, -485-3p, -485-5p, -615-5p and 
-758; (2) and a second one bearing the upregulated miR-
NAs and consists of miR-155, -363 and -886-3p. Inter-
estingly, among those identified miRNAs, there are ones 
that have already been demonstrated to regulate MSCs’ 
behavior. For instance, miR-27a has been reported to 
regulate osteogenesis of MSCs [31] whilst miR-145, -194, 
and -199a have been described to regulate their chon-
drogenesis [32–34]. Moreover, miR-221 has been shown 
to be involved in the adipogenesis process of MSCs [35]. 
Besides its ability to regulate adipogenesis [35], miR-155 
has also been described to modulate the responses of 
MSCs to inflammatory signals [36]. Furthermore, miR-
886-3p overexpression has been shown to inhibit MSCs 
migration [37].
Given that a variety of genes, encoding cell adhesion 
molecules, co-stimulatory elements as well as immu-
noregulatory cytokines and factors, are modulated in 
inflammation-primed FSK–MSCs, it is strongly pos-
sible that the differentially expressed miRNAs could be 
involved in the regulatory processes accounting for such 
altered transcription programs in inflammation-primed 
vs. non-primed FSK–MSCs. This proposal is strongly 
supported by the observation that miR-155 expres-
sion can be modulated upon inflammation-priming of 
mouse MSCs and that miR-155 expression levels are 
tightly related to its ability to modulate the immunosup-
pressive capacity of those MSCs [36], thus providing a 
striking evidence for the importance of miRNAs in reg-
ulating the immunoregulatory capacity of MSCs. To get 
more insight into the potential mechanisms and signal-
ing events that could be targeted by our differentially 
expressed miRNAs, we searched for the predicted target 
pathways of those miRNAs. In fact, given that multiple 
miRNAs may cooperate to regulate related target genes 
in a certain signaling route [38, 39], analysis of target 
pathways instead of individual genes was carried out. The 
miRNAs, being downregulated in inflammation-primed 
FSK–MSCs, are predicted to target pathways enriched in 
genes involved in Adherens junction, PI3-AKT pathway, 
apoptosis pathway, Wnt/Ca2+ pathway and leukocyte 
trans-endothelial migration. On the other hand, adherens 
junction, TNF and NF-KB signaling pathways are pre-
dicted to be the targets of miR-155 which is upregulated 
Table 2 Significantly enriched KEGG pathways (p < 0.05) targeted by miRNAs
KEGG pathways, number of target genes, and p values were identified by DIANA miRPath v.3.0 for statistically significant differentially expressed miRNAs in 
inflammation primed FSK–MSCs vs. untreated control cells
miRNA Term_ID Term_name Gene_count p value
hsa‑miR‑27a‑3p hsa04520 Adherens junction 21 0.01
hsa‑miR‑27a‑3p hsa04151 PI3‑AKT signaling pathway 78 0.03
hsa‑miR‑27a‑3p hsa‑04115 Apoptosis signaling pathway 21 0.01
hsa‑miR‑145 hsa04310 Wnt/Ca2+ signaling pathway 40 0.02
hsa‑miR‑145 hsa04520 Adherens junction 32 6.9 x 10−8
hsa‑miR‑145 hsa04151 PI3‑AKT signaling pathway 99 0.005
hsa‑miR‑145 hsa‑04115 Apoptosis signaling pathway 26 0.005
hsa‑miR‑199a‑5p hsa04520 Adherens junction 8 0.001
hsa‑miR‑194‑5p hsa04520 Adherens junction 8 0.0004
hsa‑miR‑221‑3p hsa‑04115 Apoptosis signaling pathway 13 0.007
hsa‑miR‑221‑3p hsa04670 Leukocyte transendothelial migration 14 0.02
hsa‑miR‑423‑5p hsa04520 Adherens junction 14 0.03
hsa‑miR‑485‑5p hsa04310 Wnt/Ca2+ signaling pathway 7 0.02
hsa‑miR‑155 hsa04520 Adherens junction 13 0.01
hsa‑miR‑155 hsa04064 NF‑Kappa B signaling 16 0.002
hsa‑miR‑155 mmu04668 TNF signaling pathway 22 0.001
hsa‑miR‑155 hsa04520 Adherens junction 13 0.01
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in inflammation-primed FSK–MSCs. Indeed, it was 
previously reported that miR-155, being upregulated in 
inflammation primed mouse MSCs, modulates MSCs 
immunosuppressive capacity upon modulating NF-KB 
activity [36].
The observed altered miRNA expression profile in 
inflammation-primed vs. non-primed FSK–MSCs 
imposes a detailed mechanistic characterization of the 
involvement of each of the identified miRNAs as well as 
their predicted pathway(s) on FSK–MSCs inflammatory 
responses in future studies. However, our observations 
might provide an early step toward developing a novel 
strategy to improve the immunosuppressive activity of 
FSK–MSCs. For instance, identifying the miRNAs that 
either dampen or trigger the expression of genes encod-
ing immunosuppressive cytokines, factors and receptors 
would enable us to trigger, in vitro, the immunomodula-
tory capacity of FSK–MSCs by downregulating or upreg-
ulating the expression of certain miRNAs. This, in vitro, 
pre-activation of FSK–MSCs would greatly improve their 
therapeutic potential and medical value.
Conclusions
In this report, we show that inflammation-priming of 
FSK–MSCs substantially alters their miRNA expression 
profile where 13 miRNAs are downregulated and 3 oth-
ers are upregulated. Those differentially expressed miR-
NAs are predicted to target several candidate signaling 
pathways being involved in regulating cellular behavior in 
response to inflammatory signals.
Aware that the in vivo communication between grafted 
MSCs and the host inflammatory microenvironment 
orchestrates the plasticity of the immunological proper-
ties of the grafted MSCs, understanding the molecular 
events that transplanted MSCs undergo upon exposure 
to an inflammatory signal is of great importance. In this 
report, we highlight a potential role for miRNAs in regu-
lating FSK–MSCs’ responses to inflammatory signals. 
Further, we suggest that miRNAs could serve as poten-
tial targets to improve, in vitro, the therapeutic value of 
MSCs before being grafted into the patient.
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